Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Distinguishing benign from malignant prostate disease.

Ian Thompson1

  • 1Chairman, Department of Surgery, Brooke Medical Center, San Antonio, Texas.

The Canadian Journal of Urology
|June 1, 1997
PubMed
Summary

Accurately distinguishing prostate cancer from benign conditions is crucial with rising cancer rates. This article reviews screening tests like prostate-specific antigen and digital rectal exams, and discusses valuable confirmatory diagnostic methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The BrainWaves study of adolescent wellbeing and mental health: Methods development and pilot data.

PloS one·2025
Same author

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups.

Nature genetics·2025
Same author

Author Correction: Genetically adjusted PSA levels for prostate cancer screening.

Nature medicine·2025
Same author

Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.

BJU international·2024
Same author

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

JAMA network open·2024
Same author

Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.

JAMA network open·2024

Area of Science:

  • Oncology
  • Urology
  • Medical Diagnostics

Background:

  • Increasing incidence and prevalence of prostate cancer necessitate improved diagnostic accuracy.
  • Current screening methods like prostate-specific antigen (PSA) tests and digital rectal examinations (DRE) can yield abnormal results, raising diagnostic questions.
  • Distinguishing benign prostatic conditions from malignant prostate cancer is a significant clinical challenge.

Purpose of the Study:

  • To explore the accuracy of screening tests for prostate cancer.
  • To evaluate the sensitivity, specificity, and predictive value of common prostate cancer screening tests.
  • To identify the most valuable confirmatory diagnostic tests for men with abnormal screening results.

Main Methods:

  • Review of existing literature on prostate cancer screening and diagnostic tests.
  • Analysis of the performance characteristics (sensitivity, specificity, predictive value) of various diagnostic modalities.
  • Comparative evaluation of confirmatory tests following abnormal screening results.

Main Results:

  • Abnormal screening tests require careful interpretation of their diagnostic accuracy.
  • The choice of confirmatory test depends on balancing sensitivity, specificity, and predictive value.
  • Further research is needed to optimize the diagnostic pathway for prostate cancer.

Conclusions:

  • Accurate differentiation between benign and malignant prostate disease is essential.
  • Understanding the performance metrics of screening tests is critical for clinical decision-making.
  • Selecting the most appropriate confirmatory test improves diagnostic yield and patient management.

Related Experiment Videos